Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting Rapid completion of Phase 2 enrollment signals further momentum for the development of rusfertide in polycythemia vera
News provided by
Share this article
Share this article
NEWARK, Calif., April 27, 2021 /PRNewswire/ Protagonist Therapeutics, Inc. ( Protagonist or the Company ) (Nasdaq: PTGX), today announced the completion of enrollment for the Company s Phase 2 study of rusfertide (PTG-300) in polycythemia vera ( PV ). Enrollment easily exceeded the targeted 50 evaluable patients for the study. Those patients eligible for enrollment, but unable to participate in the Phase 2 study, will have the opportunity to enroll in the planned upcoming Phase 3 study, which was announced in March 2021.
Castle Biosciences Inc (CSTL) to Acquire Myriad myPath Laboratory streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cigna said it would begin covering the biotech company s early-detection skin cancer test.
Shares were up 15.9% as of 11:48 a.m. EDT today on the news.
The DermTech PLA patch. Image source: DermTech.
So what
Virtually all of the value for DermTech, an early-stage genomics company, is tied to forecasts for its Pigmented Lesion Assay (PLA), an adhesive patch that offers a noninvasive way of detecting melanoma, disrupting conventional biopsies that require a skin sample and testing in a lab. That Cigna, a health insurance company worth nearly $100 billion, is now covering the patch represents a significant step forward for the technology as it hopes to gain widespread adoption.
Share this article
Share this article
LONDON, April 22, 2021 /PRNewswire/ GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company s Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Arterial Thromboembolism Risk Varies Across Cancer Types, Ages medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.